2-Indolinone Derivatives as Multi-Target Kinase and HDAC Inhibitors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments using multi-target kinase inhibitors face limitations in efficacy and are associated with significant side effects, and there is a need for compounds that can effectively inhibit both protein kinases and histone deacetylases to treat diseases like hematological malignancies and solid carcinomas with improved selectivity and lower toxicity.
Innovation Solution
Development of 2-indolinone derivatives that selectively inhibit protein kinases and histone deacetylases, offering anti-angiogenesis, anti-proliferation, differentiation-inducing, immune modulation, cell cycle arrest, and apoptosis-induction activities, thereby overcoming side effects of existing RTK inhibitors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multi-target kinase inhibitors are used to treat cancer, then the efficacy against solid tumors is improved, but the treatment side effects increase significantly
Solution Approach 1:
The patent combines two distinct therapeutic mechanisms into a single compound: protein kinase inhibition and histone deacetylase inhibition. The 2-indolinone derivatives are designed to simultaneously inhibit multiple protein kinases (including VEGFR2, PDGFRβ, FLT3, KIT) and HDAC enzymes, creating a multi-functional inhibitor that addresses both angiogenesis and cell proliferation through a single molecular entity
Solution Approach 2:
The 2-indolinone derivative compounds serve multiple therapeutic functions simultaneously: they inhibit protein kinase activity, inhibit histone deacetylase activity, induce cell cycle arrest, and induce apoptosis. This multi-functionality allows a single compound to address multiple pathological processes in cancer, including angiogenesis, cell proliferation, and epigenetic regulation, thereby improving efficacy while potentially reducing the need for multiple separate medications
2Reliability
If single-target therapy is used to treat cancer, then the selectivity is improved, but the cancer cells can regroup and redeploy along new growth paths
Solution Approach 1:
The patent merges the functions of multiple single-target inhibitors into one compound by designing 2-indolinone derivatives that can simultaneously bind to and inhibit multiple protein kinase targets and HDAC enzymes. This combinatorial approach ensures that cancer cells cannot easily bypass all inhibited pathways simultaneously, preventing resistance development while maintaining the selectivity benefits of targeted therapy
Solution Approach 2:
The multi-functional 2-indolinone compounds address multiple cancer-relevant pathways concurrently: VEGFR2/PDGFRβ signaling (angiogenesis), RAF/MEK/ERK pathway (cell proliferation), FLT3/KIT (hematological malignancies), and HDAC-mediated epigenetic regulation. This broad yet selective multi-functionality prevents cancer cells from adapting to a single therapeutic pressure
Data Source
AI summary
The present invention relates to 2-indolinone derivatives which are capable of inhibiting protein kinases and histone deacetylases. The compounds of this invention are therefore useful in treating diseases associated with abnormal protein kinase activities or abnormal histone deacetylase activities. Pharmaceutical compositions comprising these compounds, methods of treating diseases utilizing pharmaceutical compositions comprising these compounds, and methods of preparing these compounds are also disclosed.